CFTR and cystic fibrosis: In CF, the pharmacological inhibition of HDACs, especially using SAHA seems encouraging as this provides twofold benefit of controlling the inflammation (Hull et al., 2016; Xu et al., 2017) and also function as a proteostasis regulator (Bouchecareilh et al., 2012; Han et al., 2015) to facilitate rescue and trafficking of F508del-CFTR to the PM (CFTR-corrector) (Bodas et al., 2018a).